rituximab,polatuzumab vedotin
roche
['dlbcl', 'lymphoma', 'polarix']
race/ethnicity have impacted the inclusion in frontline clinical trials for dlbcl due to the lab-based eligibility criteria, and so the prognosis by , presenter #lymphoma #ash22 
Medical degree at @USAL | Internal Medicine student at @HematoCAUSA | Hematology and Hemotherapy at Hospital Ramón y Cajal @HematoRYC | PhD student at @UAHes